• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Small molecule that inhibits androgen receptor could treat prostate cancer


Senior Member
Maybe you should send this to WPI???? Or post it to their site? ~Fern

A good idea ! ... thanks Fern

Here is some further information

In vitro and mouse studies identified a small molecule from Geodia lindgreni that inhibits androgen receptor and could treat prostate cancer. Screening and in vitro testing of marine sponge extracts identified a compound that inhibited the N-terminal domain of androgen receptor. In three human prostate cancer cell lines, the compound reduced androgen receptor-dependent proliferation compared with no treatment. In mice with androgen-sensitive and castration-resistant prostate cancer (CRPC) xenografts, the compound reduced tumor growth compared with no treatment. Ongoing work includes optimization of the lead compound.
MDV3100, a triple-acting oral anti-androgen receptor from Medivation Inc. and Astellas Pharma Inc., is in Phase III testing to treat CRPC.
Tokai Pharmaceuticals Inc.'s TOK-001, a selective androgen receptor modulator (SARM) and inhibitor of cytochrome P450 17 a-hydroxylase/C17, 20 lyase (CYP17), is in Phase I/II testing to treat CRPC.
Aragon Pharmaceuticals Inc.'s ARN-509, a small molecule that binds androgen receptor, is in preclinical development to treat CRPC.

Patented by The University of British Columbia and the BC Cancer Agency; licensing status undisclosed

Andersen, R.J. et al. Cancer Cell; published online June 13, 2010;
Contact: Marianne D. Sadar,
BC Cancer Agency, Vancouver,
British Columbia, Canada